Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone

Blood

Volumn 100, Issue 1, 2002, Pages 48-51

  Koc, Sibel ^a,b   Leisenring, Wendy ^a,b   Flowers, Mary E D ^a,b   Anasetti, Claudio ^a,b   Joachim Deeg, H ^a,b   Nash, Richard A ^a,b   Sanders, Jean E ^a,b   Witherspoon, Robert P ^a,b   Storb, Rainer ^a,b   Appelbaum, Frederick R ^a,b   Martin, Paul J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; METHOTREXATE; PREDNISONE; STEROID;

ADOLESCENT; ADULT; AFFECTIVE NEUROSIS; ARTICLE; AVASCULAR NECROSIS; CATARACT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GLUCOSE INTOLERANCE; GRAFT VERSUS HOST REACTION; GROWTH RETARDATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RISK FACTOR; SIDE EFFECT; SKIN ATROPHY; SLEEP DISORDER; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT GAIN;

EID: 0036660429     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.48     Document Type: Article

References (14)

1. Sullivan KM. Graft-versus-host disease. In: Thomas ED, Blume KJ, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd edition. Malden, MA: Blackwell; 1999:515-536.
2. Vogelsang GB. How I treat graft-versus-host disease. Blood. 2001;97:1196-1201.
3. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-554.
4. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97:1219-1226.
5. Axelrod L. Glucocorticoid therapy. Medicine. 1976;55:39-65.
6. Sullivan KM, Witherspoon RB, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555-561.
7. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
8. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57:267-276.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74:1428-1435.
12. Storb R, Leisenring W, Anasetti C, et al. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant. 1997;3:194-201.
13. Kansu E, Gooley T, Flowers MED, et al. Administration of cyclosporine for 24 months versus 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood. 2001;98:3868-3870.
14. Deeg HJ. Graft-versus-host disease: facts and thoughts on recent developments. Curr Opin Organ Transplant. 2000;5:352-357.